Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01421212 · ClinicalTrials.gov registry record · Phase 1
Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation
A Phase 1 study of Hepatitis B Virus Associated Liver Disease, sponsored by Biotest Pharmaceuticals Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 11
- Study locations
NCT01421212 is a Phase 1 study of Hepatitis B Virus Associated Liver Disease that has completed, run by Biotest Pharmaceuticals Corporation. The registered enrollment target is 30 participants. The trial reports 11 study locations across 8 states.
The verdict
NCT01421212, a Phase 1 study of Hepatitis B Virus Associated Liver Disease, has completed, sponsored by Biotest Pharmaceuticals Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to find the best monthly dose schedule for the new Hepatitis Immune Globulin (Boca HBVIg, a study drug) when used in combination with an antiviral agent Lamivudine after liver transplantation. Boca HBVIg will be given along with Lamivudine to prevent hepatitis B reinfection following liver transplantation in patients with end stage liver failure due to hepatitis B infection.
Conditions Studied
Interventions
- BIOLOGICAL Hepatitis B Immune Globulin (Boca HBVIg)
Study Locations (11)
Florida
- University of Florida - Gainesville
- Mayo Clinic Jacksonville - Jacksonville
- Jackson Memorial Hospital / University of Miami - Miami
New York
- Mount Sinai Medical Center - New York
- New York-Presbyterian Hospital Columbia-Presbyterian Medical Center - New York
California
- University of California, San Francisco - San Francisco
Illinois
- Rush-Presbyterian - St. Luke's Medical Center - Chicago
Michigan
- The University of Michigan Health System - Ann Arbor
Minnesota
- Rochester Methodist Hospital - Rochester
North Carolina
- The University of North Carolina Hospitals - Chapel Hill
Virginia
- Medical College of Virginia Commenwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1999-11 |
| Est. Completion | 2002-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01421212
The ClinicalTrials.gov registry entry for NCT01421212 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biotest Pharmaceuticals Corporation, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatitis B Virus Associated Liver Disease appearing as the primary indexed condition, and to 1 intervention - of which Hepatitis B Immune Globulin (Boca HBVIg) is the first listed.
NCT01421212 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Florida, New York, California.
Frequently Asked Questions
What is clinical trial NCT01421212 about?
NCT01421212 is a clinical study titled "Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation". The purpose of this study is to find the best monthly dose schedule for the new Hepatitis Immune Globulin (Boca HBVIg, a study drug) when used in combination with an antiviral agent Lamivudine after liver transplantation. Boca HBVIg will be given along with Lamivudine to prevent hepatitis B reinfect...
What is the current status of trial NCT01421212?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 1999-11. Estimated completion is 2002-02.
What conditions does trial NCT01421212 study?
This clinical trial studies the following conditions: Hepatitis B Virus Associated Liver Disease.
What interventions are being tested in trial NCT01421212?
The interventions under investigation include: Hepatitis B Immune Globulin (Boca HBVIg) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01421212?
This trial is sponsored by Biotest Pharmaceuticals Corporation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01421212 being conducted?
This trial has 11 study locations across California, Florida, Illinois, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.